Search Results
Advertisement
Your search for Lee S. Schwartzberg, MD matches 2 pages
Showing 1 - 2FDA Approves Panitumumab Plus FOLFOX for Wild-Type KRAS Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer. This approval converts the accelerated...
Similar Progression-Free Survival With Panitumumab vs Bevacizumab Plus Modified FOLFOX6 in Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
In a phase II trial (PEAK) reported in the Journal of Clinical Oncology, Schwartzberg et al compared the EGFR inhibitor panitumumab (Vectibix) vs the VEGF-A inhibitor bevacizumab (Avastin) combined with modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) in patients with previously...
Advertisement
Advertisement
Apr
Today In Oncology19
Advertisement
© 2024 HSP News Service, L.L.C.
